Atossa Therapeutics’ Q4 2024 Earnings Call: A Detailed Analysis
On March 25, 2025, Atossa Therapeutics, Inc. (NASDAQ: ATOS) held its Fourth Quarter and Full Year 2024 Earnings Conference Call. The call was hosted by Michael Parks, VP of Investor and Public Relations, Steven Quay, President and CEO, and Heather Rees, CFO. Here’s a brief summary of the key points discussed during the call:
Company Participants
Michael Parks began the call by welcoming everyone and introducing the participants. He then handed the floor over to Steven Quay, who provided an overview of the company’s financial performance and operational highlights for the quarter.
Financial Performance
Steven Quay: Our total revenue for the quarter was $12.5 million, up from $10.2 million in the same period last year. Our net loss was $16.3 million, compared to $12.8 million in the same period last year. This increase in net loss was primarily due to increased research and development expenses as we continue to advance our pipeline.
Operational Highlights
Steven Quay: In the fourth quarter, we initiated a Phase 2b/3 clinical trial for our proprietary investigational breast cancer treatment, Endoxifen. We also announced positive results from our Phase 2 study of our proprietary topical treatment for actinic keratosis, AT101. We have completed enrollment in our Phase 3 study for this indication and expect to report top-line data in the second half of 2025.
Conference Call Participants
The call then opened up for questions from conference call participants. Emily Bodnar from H.C. Wainwright asked about the commercial potential of Endoxifen, and Steven Quay provided an update on the progress of the Phase 2b/3 clinical trial. Edward Woo from Ascendiant Capital inquired about the potential competition for AT101, and Heather Rees addressed this concern by discussing the unique mechanism of action and competitive advantages of Atossa’s topical treatment.
Impact on Individuals
For those of you who may be diagnosed with breast cancer or actinic keratosis, the progress Atossa Therapeutics is making in the development of Endoxifen and AT101 could potentially lead to new treatment options. Endoxifen is a selective estrogen receptor modulator (SERM) that has the potential to provide an alternative to current hormonal therapies for breast cancer. AT101, on the other hand, is a topical treatment for actinic keratosis, a common precursor to skin cancer, that could offer a more convenient and less invasive treatment option compared to current therapies.
Impact on the World
On a larger scale, the advancements made by Atossa Therapeutics could have a significant impact on the healthcare industry, particularly in the areas of breast cancer and dermatology. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are expected to be diagnosed in the United States in 2025. New, effective treatments for breast cancer could save countless lives and improve the quality of life for those who are diagnosed. Additionally, AT101 could potentially reduce the number of cases of skin cancer by offering a more accessible and effective treatment option for actinic keratosis.
Conclusion
In conclusion, the Atossa Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call provided valuable insights into the company’s financial performance and operational highlights. The progress being made in the development of Endoxifen and AT101 could lead to new, potentially life-saving treatment options for those diagnosed with breast cancer and actinic keratosis, respectively. These advancements could have a significant impact on the healthcare industry and could potentially save countless lives and improve the quality of life for millions of people.
- Atossa Therapeutics reported total revenue of $12.5 million for Q4 2024, up from $10.2 million in the same period last year.
- Net loss for Q4 2024 was $16.3 million, compared to $12.8 million in the same period last year.
- Steven Quay provided an update on the progress of the Phase 2b/3 clinical trial for Endoxifen.
- Heather Rees addressed concerns about competition for AT101 and discussed the unique mechanism of action and competitive advantages of Atossa’s topical treatment.
- Endoxifen is a potential alternative to current hormonal therapies for breast cancer.
- AT101 is a topical treatment for actinic keratosis that could offer a more convenient and less invasive treatment option compared to current therapies.
- The advancements made by Atossa Therapeutics could have a significant impact on the healthcare industry and potentially save countless lives and improve the quality of life for millions of people.
